Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9Y1XB)

Drug Name

ABT-RTA-408 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Nuclear factor erythroid 2-related factor 2 (Nrf2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Omaveloxolone	DMLMNFX	Friedreich's ataxia	8A03.10	Approved	[3]
CXA10	DMM7Z6K	Focal segmental glomerulosclerosis	MF8Y	Phase 2	[4]
SFX-01	DMAQW9M	Breast cancer	2C60-2C65	Phase 2	[5]
OT-551	DMTNOXQ	Ocular inflammation	9C61.24	Phase 2	[6]
OT551	DMHKIOF	Age-related macular degeneration	9B75.0	Phase 2	[7]
HPP971	DMZXG7Q	Non-alcoholic steatohepatitis	DB92.1	Phase 1	[8]
PMID28454500-Compound-57	DMTK9M6	N. A.	N. A.	Patented	[9]
PMID28454500-Compound-8	DM6BQFA	N. A.	N. A.	Patented	[9]
Pyrazino[2,1-a]isoquinolin derivative 4	DMKTNBC	N. A.	N. A.	Patented	[9]
PMID28454500-Compound-36	DM5RZWG	N. A.	N. A.	Patented	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nuclear factor erythroid 2-related factor 2 (Nrf2)	TTA6ZN2	NF2L2_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02142959) RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE. U.S. National Institutes of Health.
2	National Cancer Institute Drug Dictionary (drug id 756624).
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.
5	Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
6	New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.
7	Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325.
8	Clinical pipeline report, company report or official report of vTv Therapeutics.
9	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.